Venus Remedies (NSE:VENUSREM) Construction In Progress: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:VENUSREM Venus Remedies Ltd NSE:VENUSREM
58 GF Score
Price ₹1,775.50
GF Value ₹466.33
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Venus Remedies Construction In Progress?

Venus Remedies NSE:VENUSREM +4.82% 58 Construction In Progress is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:VENUSREM with a GF Score™ of 58/100 and a GF Value™ of ₹466.33 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Venus Remedies's quarterly construction in progress increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹514 Mil) but then declined from Mar. 2026 (₹514 Mil) to Jun. 2026 (₹0 Mil).

Venus Remedies's annual construction in progress increased from Mar. 2024 (₹220 Mil) to Mar. 2025 (₹289 Mil) and increased from Mar. 2025 (₹289 Mil) to Mar. 2026 (₹514 Mil).

Venus Remedies Construction In Progress Historical Data

* Premium members only.

The historical data trend for Venus Remedies's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Venus Remedies Construction In Progress Chart

Venus Remedies Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 657.82 671.53 219.73 288.65 513.60

Venus Remedies Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 340.10 0.00 513.60 0.00
NSE:VENUSREM
58GF Score
Venus Remedies Ltd NSE:VENUSREM
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Venus Remedies Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ₹0 Mil mean?
Venus Remedies (NSE:VENUSREM) has a Construction In Progress of ₹0 Mil as of Jun. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Venus Remedies and its competitors.
Is Venus Remedies' Construction In Progress too high?
Venus Remedies' current Construction In Progress is ₹0 Mil. Overall, Venus Remedies has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Venus Remedies' Construction In Progress compare to ZTS and UTHR?
Venus Remedies' Construction In Progress of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Venus Remedies and its competitors. Venus Remedies's current Construction In Progress is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Remedies stock overvalued right now?
Based on GuruFocus' analysis, Venus Remedies (NSE:VENUSREM) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹466.33, compared to a current price of ₹1,775.50 — trading 280.7% above its estimated fair value. The current Construction In Progress is ₹0 Mil. Venus Remedies' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Venus Remedies (NSE:VENUSREM), the current Construction In Progress is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Venus Remedies (NSE:VENUSREM) Overvalued in 2026?

Based on GuruFocus' analysis, Venus Remedies stock appears to be overvalued. The current stock price of ₹1,775.50 is trading 280.7% above its estimated GF Value™ of ₹466.33. GuruFocus considers Venus Remedies to be Significantly Overvalued.

Key valuation signals for NSE:VENUSREM:

  • Construction In Progress: ₹0 Mil
  • GF Value™: ₹466.33 vs. price of ₹1,775.50 (280.7% above fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the NSE:VENUSREM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Venus Remedies Business Description

Other Exchanges 526953:India
Address Plot 51-52, Industrial Area, Phase 1, Panchkula, HR, IND, 134113
Venus Remedies Ltd is an Indian drug manufacturer. It is engaged in manufacturing and trading pharmaceutical products. The company produces biologically active food supplements which include food supplements are natural complexes containing minerals, vitamins, dietary fibers, extracts of medicinal herbs, amino acids and others.
58GF Score

Get the complete analysis for NSE:VENUSREM

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,775.50
Price
₹466.33
GF Value